Episode 9: Bouldering & Biomedical Entrepreneurship | John Criscione

Dr. John Criscione is a professor of Biomedical Engineering at Texas A&M University who trains medical device engineers while simultaneously inventing, testing, and commercializing medical technologies. Dr. Criscione has been serving in this capacity for over 20 years and also serves as the CTO for CorInnova, a biomedical technology company focused on addressing Acute Heart Failure.

During our conversation, he discusses:

* The importance of disagreement for innovation

* Translating inventions into marketable products

* The challenges of new technologies and indications in medical devices

* The pivotal role of angel investors in technology development

* Navigating the 'valley of death' in medical technology commercialization

* The specific difficulties of pediatric medical devices

* Partnering for commercialization versus solo invention

* The role and impact of the Southwest Pediatric Device Consortium

Listen now on Spotify, Apple Podcasts, and YouTube.

What We Cover:

* 00:00 The Nature of Innovation

* 04:08 John’s Journey into Biomedical Engineering

* 06:09 Challenges in Medical Technology

* 10:47 The Valley of Death in Medical Innovation

* 13:57 Funding and Investment Challenges

* 15:12 CorInnova's Inception and Early Years

* 20:51 The Double Whammy of New Technologies

* 25:59 The Role of Angel Investors

* 28:33 The Burdens of Innovation

* 35:52 Challenges in Pediatric Medical Devices

*

Know someone who would enjoy this episode? Share it with them!

P.S. Your feedback is important to me. Also, it tells the algorithms to pay more attention, which helps me out a lot. If you enjoyed this episode, hit the "like" button or leave a comment with your thoughts.

Want more?

• Get essential angel intel straight to your inbox every week with The Diligent Observer Newsletter.
• Check out the entire show library and follow via Apple Podcasts, Spotify, and YouTube.

Connect with Andrew

LinkedIn | X | Angel Ops E-Book

All opinions are personal and may not reflect the views of The Diligent Observer. Not investment advice.